FDA sets up new safety council to keep tabs on approved vaccines, cell and gene therapies

FDA
The idea, according to the FDA, is to make sure post-marketing safety oversight of CBER-regulated products—from vaccines and genetic medicines to blood and blood products—is conducted via “a dedicated, cross-functional team with clear lines of accountability.” (Stock Photo )

Though the quest to locate the regulator’s next commissioner hit a snag this week, the FDA has nevertheless been bringing some stability back to its key departments overseeing small molecule drugs and biologics in recent months. 

Now, in an evolution of the safety working group (SWG) that has long existed there, the agency’s Center for Biologics Evaluation and Research (CBER) is setting up a new governance body focused on safety oversight of products like cell and gene therapies and vaccines once they’ve hit the market, coming at a time when public trust in science and medical interventions in the U.S. is fragile, to say the least. 

Dubbed the CBER Safety Council, the new unit will operate independently from the CBER product offices that weigh in on approvals of the biologics the Center oversees, instead reporting straight to its director-—Karim Mikhail—who assumed the post permanently in September after serving in an acting capacity. 

The idea, according to an FDA notice Thursday, is to make sure post-marketing safety oversight of CBER-regulated products—from vaccines and genetic medicines to blood and blood products—is conducted via “a dedicated, cross-functional team with clear lines of accountability.” 

The Safety Council will in turn establish a “layer of review that is distinct from the product offices that conduct premarket approval,” the FDA explained, highlighting the need for safety assessments post-approval that are “comprehensive and consistent,” as well as clear communication of that scientific evidence to the public. 

The specific remit of the Safety Council covers reviews and assessments of safety signals across all CBER-regulated products on the market, the performance of benefit-risk assessments to inform potential regulatory action recommendations, suggestions to CBER around matters like safety labeling changes and risk evaluation and mitigation strategies, and input on potential actions by CBER related to safety-related market withdrawals.

The CBER Safety Council will also be tasked with publishing public-facing safety communications “promptly after significant safety determinations,” the FDA explained. 

With the post of Senior Advisor for Postmarketing Safety at the top of the new unit, the CBER Safety Council will also leverage analytical resources from other agency divisions, including the Division of Pharmacovigilance, the CBER Surveillance Program and the Division of Analytics and Benefit-Risk Assessment.

The Council was officially established on Nov. 19, with the FDA noting that more information about its structure, membership and operating procedures is to come. 

In an interview with Fierce in October, CBER chief Mikhail said that he saw a key part of his role as working to restore public trust in his department, and the FDA more broadly, specifically suggesting that, at times, he wishes the public would be more closely tuned into the debates and safety discussions ongoing at the regulator. 

“This is a top priority for me—making sure we are as transparent as possible in our decision-making,” Mikhail vowed at the time. “Anything that we can make public, we will make public because that will enhance public trust.”

Mikhail became the leader of CBER on a permanent basis in September, at the same time that the FDA firmed up Michael Davis, M.D., Ph.D.’s position at the top of sister department the Center for Drug Evaluation and Research. At the time, acting FDA commissioner Kyle Diamantas framed the move not as simply filling vacancies but as a signal of “the direction we are heading.”

Leadership turnover has been swift and dramatic at the FDA since the Trump administration returned to the White House in 2025, both at the top—where the departure of former commissioner Marty Makary, M.D., in May has left a vacuum that has yet to be filled—and at departments like CBER specifically, which endured the ouster of Peter Marks, M.D., Ph.D., last year before the ill-fated appointments of Vinay Prasad, M.D. and Katherine Szarama, Ph.D. 

Mikhail, who stepped up to the CBER helm on an acting basis in May, expressed faith in the scientific background of the White House’s most recent nomination for FDA commissioner in Heidi Overton, M.D., Ph.D., when he spoke to Fierce this fall. 

Still, the White House ultimately pulled its nomination for Overton just hours before a scheduled Senate vote on her confirmation this week. The decision followed a stark reversal of Republican power during the U.S. midterm elections in early November, plus a contentious hearing that Overton attended before the Senate Health, Education, Labor and Pensions (HELP) Committee in September.